Medical Device Outsourced Manufacturing Market: as contract manufacturers such as Integer Holdings acquire specialised coating and micro-machining capability rather than simply expanding assembly capacity, the outsourced manufacturing relationship shifts from a cost-driven assembly arrangement into a genuine engineering partnership that device makers depend on for capability they do not have in-house, so contract manufacturers capable of offering proprietary process technology, not merely capacity, capture premium pricing and deeper, stickier customer relationships than pure assembly-for-hire competitors.

The global medical device outsourced manufacturing market size was USD 62.00 Billion in 2025 and is expected to register a revenue CAGR of 9.0% during the forecast period. Market revenue growth is driven by factors such as leading contract manufacturers acquiring specialised coating and micro-machining capability to offer proprietary process technology rather than assembly capacity alone, sustained double-digit sales growth at leading contract development and manufacturing organizations, and device makers increasingly outsourcing complex component engineering rather than only final assembly. The first driving factor is leading contract manufacturers acquiring specialised coating and micro-machining capability, converting the outsourced manufacturing relationship from a capacity-for-hire arrangement into a proprietary engineering partnership. Integer Holdings Corporation, a leading contract development and manufacturing organization, completed the Precision Coating acquisition for USD 152 million, adding fluoropolymer and anodic coating capability, and signed the VSi Parylene acquisition agreement, adding parylene conformal coating capability specifically for complex medical device applications. The second driving factor is sustained double-digit sales and profitability growth at leading contract development and manufacturing organizations, reflecting genuine demand strength for outsourced manufacturing services rather than a cyclical uptick. Integer Holdings Corporation reported full year 2024 sales up 10% and adjusted operating income up 20%, with CEO Joseph Dziedzic highlighting the results, while preliminary unaudited full year 2023 sales of USD 1.595 to 1.597 Billion had already increased 16% versus 2022, reflecting sustained multi-year growth momentum. The third driving factor is device makers increasingly outsourcing complex component engineering and design services rather than only final product assembly, extending the outsourced manufacturing relationship earlier into the product development lifecycle. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a contract manufacturer’s proprietary coating or micro-machining capability widens its own addressable customer relationship as device makers who need that specific process technology have no alternative supplier offering it, letting one specialised capability investment capture premium, defensible revenue across many device maker customers rather than competing purely on assembly price and capacity availability. Once a contract manufacturer acquires proprietary coating or micro-machining process technology that few or no competitors offer, device makers requiring that specific capability face a genuinely limited supplier choice, and this scarcity gives the contract manufacturer pricing power and relationship durability that a pure assembly-for-hire competitor, competing primarily on capacity and cost, does not have, so proprietary process technology and premium, sticky customer relationships are directly linked. As a result, demand and revenue share are concentrating around contract manufacturers offering proprietary, hard-to-replicate process technology, and the forecast tilts toward engineering-differentiated outsourced manufacturing partners rather than commodity assembly-for-hire competitors. For instance, in January 2025, Integer Holdings Corporation, United States, completed its acquisition of Precision Coating for USD 152 million, adding fluoropolymer and anodic coating capability that device makers requiring these specific coating processes for implantable and surgical device components now depend on Integer specifically to provide, illustrating how proprietary process technology acquisition converts a contract manufacturing relationship into a defensible, differentiated engineering partnership. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is leading contract manufacturers acquiring specialised coating and micro-machining capability that device makers cannot easily source elsewhere. A device maker needing a specific coating process, such as fluoropolymer or parylene conformal coating for an implantable device component, faces a genuinely limited supplier pool once that capability concentrates within a small number of specialised contract manufacturers, and this concentration gives the contract manufacturer holding that capability durable customer relationships rather than commodity, price-competed ones, so proprietary process acquisition and customer relationship durability are directly linked. Integer Holdings Corporation completed its acquisition of Precision Coating for USD 152 million, adding fluoropolymer and anodic coating capability, and signed the VSi Parylene acquisition agreement, adding parylene conformal coating capability specifically for complex medical device applications. The effect on the market is that contract manufacturer competitive positioning increasingly depends on proprietary process technology ownership rather than assembly capacity and price alone. These are some of the key factors driving revenue growth of the market.

The second driver is the sustained, multi-year sales and profitability growth pattern documented at leading contract development and manufacturing organizations, distinguishing genuine structural demand growth from a short-term cyclical uptick. A single strong year could reflect cyclical timing, but a multi-year pattern of double-digit sales growth alongside faster-growing adjusted operating income indicates device makers are structurally increasing their reliance on outsourced manufacturing capacity and capability rather than temporarily shifting production during a capacity crunch, so the multi-year growth pattern and structural outsourcing demand are directly linked. Integer Holdings Corporation reported via SEC Form 8-K that full year 2024 sales increased 10% with adjusted operating income up 20%, following preliminary unaudited full year 2023 sales of USD 1.595 to 1.597 Billion that had already increased 16% versus 2022, reflecting sustained growth momentum across consecutive fiscal years. The recent record shows the pace. Integer also confirmed completion of its Pulse Technologies acquisition in January 2024, adding highly differentiated micro-machining capability that further extended its proprietary process technology base ahead of the Precision Coating and VSi Parylene transactions completed in early 2025. The effect on the market is that leading contract manufacturers’ sustained financial performance validates the broader structural shift of device makers toward deeper outsourced manufacturing reliance. These are some of the key factors driving revenue growth of the market.

“Integer Holdings Corporation reported full year 2024 sales up 10% with adjusted operating income up 20%, following preliminary unaudited full year 2023 sales of USD 1.595 to 1.597 Billion that had already increased 16% versus 2022, a sustained multi-year growth pattern that distinguishes structural outsourced manufacturing demand strength from a short-term cyclical uptick.”

The third driver is the extension of outsourced manufacturing relationships from final assembly work into earlier-stage component engineering and design services. Design and engineering services delivered by a contract manufacturer with deep process technology expertise can identify manufacturability improvements earlier in a device’s development than a device maker working with a contract manufacturer purely for late-stage assembly, and this earlier engagement is what has extended the outsourcing relationship earlier into the product lifecycle, so proprietary process expertise and earlier-stage outsourcing engagement are directly linked. Device makers working with contract manufacturers holding specialised coating, micro-machining, and materials engineering expertise increasingly engage those partners during device design rather than only at production scale-up, reflecting a genuine shift in how the outsourced manufacturing relationship is structured. The effect on the market is that outsourced manufacturing revenue increasingly includes higher-margin design and engineering service fees alongside traditional assembly and coating service revenue. These are some of the key factors driving revenue growth of the market.

However, the medical device outsourced manufacturing market faces adoption constraints from the quality system and regulatory qualification burden device makers face when transferring production to a new contract manufacturer, device maker concerns about protecting proprietary intellectual property when outsourcing design and engineering services, and contract manufacturer capacity concentration risk among the most capable proprietary-technology-holding suppliers. Because transferring medical device production to a new contract manufacturer requires a documented process validation and quality system qualification under applicable FDA and international regulatory requirements, device makers face a genuine, multi-month-to-multi-year switching cost that limits how quickly outsourced manufacturing relationships can shift even where a competing contract manufacturer offers superior capability or pricing, meaning contract manufacturer market share tends to shift gradually rather than rapidly even amid genuine competitive differentiation. Intellectual property protection concerns are a second constraint, because outsourcing design and engineering services, not merely assembly, requires device makers to share proprietary product design information with a third party earlier in the development process, and some device makers, particularly those developing devices with significant proprietary differentiation, remain reluctant to extend outsourcing this far into their product development process regardless of the cost or capability advantage a contract manufacturer might offer. Contract manufacturer capacity concentration is the third constraint, since the most capable, proprietary-technology-holding contract manufacturers such as Integer Holdings represent a limited supplier pool for specific coating and micro-machining processes, and device makers dependent on a specific proprietary process face genuine supply continuity risk if that contract manufacturer experiences capacity constraints, quality issues, or operational disruption, since alternative qualified suppliers for the same proprietary process may not readily exist. These factors substantially limit medical device outsourced manufacturing market growth over the forecast period.

Based on service type, the global medical device outsourced manufacturing market is segmented into contract manufacturing/assembly, specialised coating and surface treatment, and design and engineering services. Contract manufacturing/assembly holds the largest revenue share, because it remains the foundational service category underlying the outsourced manufacturing relationship across virtually every device maker customer, which suits both Integer Holdings’ and Jabil’s broad assembly capacity base. Specialised coating and surface treatment is expected to register rapid revenue growth in the global medical device outsourced manufacturing market over the forecast period, driven directly by Integer Holdings’ Precision Coating and VSi Parylene acquisitions, which is why proprietary coating capability represents the fastest-evolving service category within the broader outsourced manufacturing relationship.

Class III (high risk/implantable) device class is expected to account for a significantly large revenue share in the global medical device outsourced manufacturing market during the forecast period

Based on device class, the global medical device outsourced manufacturing market is segmented into Class I (low risk), Class II (moderate risk), and Class III (high risk/implantable) devices. Class III devices hold a significant revenue share, reflecting the highest per-unit outsourced manufacturing service value given the specialised coating, micro-machining, and validation requirements implantable devices demand. Class II devices represent the largest volume category by unit count, given the broad range of moderate-risk devices that rely on contract manufacturing, but Class III devices command a disproportionate share of revenue given their higher service value per unit.

Cardiac and neuromodulation devices application is expected to account for the largest revenue share in the global medical device outsourced manufacturing market during the forecast period

Based on application, the global medical device outsourced manufacturing market is segmented into cardiac and neuromodulation devices, surgical instruments and robotics components, and diagnostic and monitoring devices. Cardiac and neuromodulation devices hold the largest revenue share, reflecting the high value and specialised process requirements of components used in pacemakers, neurostimulators, and related implantable devices, which suits Integer Holdings’ core customer base among cardiac and neuromodulation device makers. Surgical instruments and robotics components are expected to register rapid revenue growth in the global medical device outsourced manufacturing market over the forecast period, driven by continued multi-manufacturer investment in robotic-assisted surgical platform expansion, which is why contract manufacturers are increasingly building robotics-specific component engineering capability.

Based on regional analysis, the medical device outsourced manufacturing market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of both device makers and leading contract manufacturers, including Integer Holdings Corporation and Jabil Inc., and because the country’s FDA regulatory framework anchors quality system qualification requirements that shape global outsourced manufacturing relationships. Integer Holdings Corporation’s Precision Coating and VSi Parylene acquisitions both concentrated proprietary process technology investment first within the United States contract manufacturing base. The concentration of leading contract manufacturers and device maker customers in the United States also means new outsourced manufacturing capability, including proprietary coating and micro-machining processes, is typically developed in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Ireland, Germany, and Switzerland represent the three largest national medical device outsourced manufacturing markets within Europe. Ireland in particular hosts substantial contract manufacturing capacity serving both European and United States device makers, and the region’s established manufacturing infrastructure and CE-marking regulatory pathway under the Medical Device Regulation sustain steady demand. The result is steady rather than rapid growth, shaped more by the region’s already-mature contract manufacturing infrastructure than by unmet capacity demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Malaysia, and India represent the three largest national medical device outsourced manufacturing markets within the region. Expanding contract manufacturing capacity investment and device maker interest in geographically diversified supply chains are driving new outsourced manufacturing demand from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Mexico and Costa Rica represent the two largest national medical device outsourced manufacturing markets within the region, both benefiting from proximity to the United States device maker customer base. Contract manufacturers in both countries are gradually expanding capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised raw materials and components that Latin American contract manufacturers depend on through 2026, slowing capacity expansion beyond the region’s established manufacturing hubs.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial medical device outsourced manufacturing markets within the GCC. The UAE is the most established medical device outsourced manufacturing market on the continent given its logistics and free-zone manufacturing infrastructure, while the wider Gulf states and broader African markets are still building the contract manufacturing base that outsourced medical device production depends on.